A policy issued by the Department of Health and Human Services (HHS), spearheaded by Robert F. Kennedy Jr., aims to ease access to unproven peptide drugs. This policy directs the Food and Drug Administration (FDA) not to take action against specialty pharmacies selling a handful of peptides, including BPC-157, TB-500, and KPV. These chemicals are currently considered illegal drugs by the FDA because they have not undergone the agency’s rigorous review process for safety and effectiveness.
Background and Rationale
The policy reflects Kennedy’s determination that it advances patient choice and protects Americans from online peptide sales. FDA scientific staffers opposed the changes, citing concerns about undermining the agency’s mission to limit unproven health products.
Implementation Measures
HHS officials initially sought a regulation allowing these peptides to be used by compounding pharmacies, but this approach was abandoned. The HHS policy includes measures such as requiring pharmacies to use peptide ingredients from registered factories and collect information on side effects. The FDA has previously warned about the safety risks of unproven peptides and added more than a dozen peptides to its list of substances that should not be compounded due to potential risks.